Introduction
Atherosclerosis is a progressive inflammatory dis-tory cell accumulation and extracellular matrix degradation contribute to fibrous cap thinning, plaque destabilization and, potentially, rupture. Plaque angiogenesis plays an important role in the destabilization of atherosclerotic lesions. In advanced plaques, inflammatory cell infiltration, and the concomitant production of numerous pro-angiogenic cytokines may lead to the induction of uncontrolled intimal neovascularization, resulting in the production of immature and fragile (leaky) vasa vasorum 4) similar to blood vessels seen in tumor development. These can serve as a port of entry for inflammatory cells, and contribute to the development of a hemorrhagic and rupture-prone environment. Increasing evidence suggests that intimal neovascularization is directly related to the stage of plaque development, the risk of plaque rupture, and subsequently, the acute clinical manifestations of atherosclerosis 5) .
As the inflammatory cell migration into the lesion and intimal neovascularization are considered crucial steps in the destabilization of atherosclerotic plaque, the inhibition of leukocyte and endothelial migration poses a challenge for effective anti-atherosclerotic therapy. Results of epidemiological studies that demonstrated an inverse correlation between dietary polyphenol intake and cardiovascular mortality (reviewed in 6) ) suggest that the powerful antiinflammatory properties of plant polyphenols (e.g. resveratrol, curcumin, epicatechin) may induce the cardioprotective response. Resveratrol (trans-3,4',5-trihydroxystilbene), the active compound of red wine, was previously shown to inhibit the activation of nuclear factor (NF)-B 7) , a transcription factor which modulates the inflammatory response in endothelial cells. It was also associated with improved endothelium-dependent vasodilation in humans 8) . Resveratrolinduced activation of sirtuin 1 (SIRT1) was shown to confer a vasoprotective phenotype in endothelial cells 9) . Moreover, as shown in our previous study, treatment with resveratrol significantly prevented TNF--induced adhesion molecule expression and monocytic cell adhesion to ECs exposed to non-uniform shear stress 10) . Apart from the inhibition of inflammatory pathways, resveratrol was previously implicated in the inhibition of cancer cell migration 11) and tumor angiogenesis 12) indicating its ability to interfere with signal transduction pathways regulating cell motility. In the context of atherosclerosis, inhibition of vascular cell migration, in particular with regard to monocytes and endothelial cells, may contribute to reduced plaque progression. In this study, we therefore investigated the effects of resveratrol on spontaneous endothelial migration and MCP-1-induced monocytic cell chemotaxis.
Methods

Materials and Reagents
Endothelial Cell Growth Medium was obtained from Promo Cell (Heidelberg, Germany). Phosphatebuffered saline (PBS, pH 7.4) and RPMI 1640 medium were purchased from Biochrom AG (Berlin, Germany). Accutase TM , penicillin, streptomycin, fetal calf serum (FCS), horse serum, and collagen-1 were from PAA Laboratories (Linz, Austria), and dispase was from Gibco (Eggenstein, Germany). TNF-was purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). Resveratrol (trans-3,4',5-trihydroxystilbene), obtained from Sigma (Munich, Germany), was dissolved in ethanol to 100 mmol/L concentration. Simvastatin, kindly provided by Merck (Rahway, NJ), was dissolved in ethanol and activated as described by Jakobisiak et al. 13) . Rho kinase (ROCK) inhibitors, Y27632 and hydroxyfasudil, as well as forskolin, rolipram, and SIRT1 inhibitor were from Calbiochem (Darmstadt, Germany). Cell-permeable selective Rho inhibitor (C3 Transferase from Clostridium botulinum) was purchased from Cytoskeleton Inc. (Denver CO, USA). To determine the appropriate C3 concentrations, the phenotypic changes (cell shape, actin cytoskeleton) were monitored over 6-30 h in HUVECs treated with C3 at 0.1-1 g/mL. Based on these studies, 2 concentrations were selected for the cell migration experiments (0.25 g/mL and 0.5 g/mL), which induced progressive phenotypic changes indicating effective Rho inhibition, but were well tolerated by the cells, i.e. did not induce marked cell toxicity after 24h incubation. Monocyte chemoattractant protein-1 (MCP-1) was from Tebu-bio (Offenbach, Germany). NF-B inhibitor BAY11-7082 ((E)-3-[(4-methylphenyl)sulphonyl]-2-propenenitrile) from Biomol (Hamburg, Germany), was dissolved in DMSO to 100 mmol/L concentration. MAP Kinase Kinase (MEK) inhibitor, U0126, was from Promega (Madison, WI, USA).
Monoclonal rabbit anti-phospho-Erk antibody, rabbit anti-Erk1/2, and rabbit antibody against the phosphorylated form of myosin phosphatase targeting subunit 1 (pMYPT1, Thr853) were obtained from Cell Signaling (Danvers, MA, USA). Rabbit anti-vinculin antibody was from Santa Cruz (Heidelberg, Germany) and HRP-conjugated anti-rabbit antibody was purchased from Amersham (Freiburg, Germany).
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated from freshly collected umbilical cords by standard techniques and grown in supplemented endothelial cell growth medium in a humidified 7.5% CO2 atmosphere. In all experiments, HUVECs at passage 1-2 were used. THP-1 monocytic cells were cultured in RPMI 1640 medium supplemented with 2 mmol/L glutamine, 100 U/mL penicillin, 100 g/mL streptomycin and 10% FCS. Cell viability was greater than 98% as estimated by Trypan blue exclusion.
Immunofluorescent Staining
The effects of resveratrol treatment on endothelial morphology were analyzed immunocytochemically. Briefly, HUVECs were fixed with 4% paraformaldehyde, followed by permeabilization with 0.2% Triton X-100 in PBS. Monoclonal antibody against vascular endothelial (VE)-cadherin (1:40) was obtained from Abcam (Cambridge, UK). F-actin fibers were visualized using Alexa 488-conjugated phalloidin (PromoKine, Heidelberg, Germany). Antimouse IgGs coupled to Alexa Fluor 555 were purchased from Molecular Probes (Karlsruhe, Germany).
Bright field photos were obtained using phase contrast. Fluorescent images were obtained using an inverted microscope (Zeiss Axiovert 100, Jena, Germany) combined with a digital camera, at 200 magnification.
As a measure of the cell shape change, the elongation index was employed: EI (L S)/(L S), where L is the length of the cell, and S the short axis. In each group, the long and the short axes of 150 VE-cadherin-stained cells from 4 independent experiments were measured using computer-aided planimetry (Lucia Software V. 4.21; Laboratory Imaging Ltd., Nuremberg, Germany).
Endothelial Cell Migration Assay
HUVEC migration was assessed in a modified barrier assay using silicone cell culture inserts from Ibidi (Munich, Germany). HUVECs were seeded in 2 wells separated by a 500 m barrier, at a concentration of 3 10 5 /mL. The cells were treated with 1-20 mol/L resveratrol overnight. Following the removal of inserts, HUVECs were washed with medium and incubated with appropriate concentrations of resveratrol for up to 24 h. The gap between the 2 monolayers was recorded at the insert removal point (0 h), and at 3, 6, 8, and 24 hours using a Nikon CCD-camera connected to the Olympus IX70 microscope, at 100 magnification. Cell-free areas at different time points were measured using computer-aided planimetry (Lucia Software V. 4.21). The effect of resveratrol on cell migration was assessed by calculating the increase in the area occupied by cells at later time points compared with the cell-covered area at 0 h. In all experiments, ethanol (at 0.02%) was used as a control for the specificity of resveratrol effects.
Chemotaxis Assay
The effect of resveratrol (1-10 mol/L, 20 h) on monocytic cell migration was assessed in a 48-well microchamber (NeuroProbe, Gaithersburg, MD, USA). Briefly, the lower wells were filled with 28 L serum-free RPMI 1640. MCP-1 (50 ng/mL) was used as a positive control. The upper wells were filled with 56 L resveratrol-treated monocytic cells at a concentration of 1 10 6 cells/mL, and separated from the lower compartment by an 8 m-pore, collagen-coated polycarbonate membrane (Nucleopore; NeuroProbe). After incubation for 1 h at 37 , the membranes were fixed in methanol and stained in DiffQuick, before scraping off the cells on the upper side of the filter membrane. Migrated adherent cells were counted in 6 high-power microscopic fields for each well. Migrated non-adherent cells from the lower wells were counted using a Bürker-Türk counting chamber. All samples were run in quadruplicate and averaged. The mean number of migrated cells in the negative control (MCP-1 unstimulated) samples was set as 1. For collagen coating, the membranes were incubated in 20 mol/L collagen-1 at 37 for 1 h. Ethanol-treated monocytic cells were used to confirm the specificity of resveratrol effects.
Western Blotting
To indirectly determine the activation of ROCK by resveratrol, HUVECs were incubated in the presence or absence of 10 mol/L resveratrol for 60 min. After treatment, the cells were washed with PBS. The lysis of cell pellets and subsequent Western blot analysis were carried out as described before 14) . pMYPT1 was analyzed using a specific antibody (1:1000) overnight. To confirm equal protein loading, the membranes were re-probed with antibody against vinculin.
Monocytic cells were incubated overnight with 1-20 mol/L resveratrol, followed by the stimulation with 50 ng/mL MCP-1 for 10 min. After treatment, the activation of Erk was analyzed using appropriate antibodies (anti-pErk 1:1000; anti-Erk1/2 1:1000; overnight), and visualized using an enhanced chemiluminescence system (ECL-Plus; Amersham).
Statistical Analyses
Data are expressed as the mean SEM, unless stated otherwise. P 0.05 was considered statistically significant. Analyses were carried out using SigmaStat ® software. The paired t -test and Mann-Whitney rank sum test were used to compare the differences between resveratrol-treated and control samples.
Results
Resveratrol Induces a Dose-and Time-Dependent Change in Endothelial Morphology
HUVECs treated with growing concentrations of resveratrol displayed progressive elongation as compared with control cells. Cell elongation was associated with the rearrangement of cell-cell contacts visualized by VE-cadherin staining (Fig. 1A) . As a measure of the cell shape change, we employed the elongation index (EI (L S)/(L S)), where EI values close to 1 indicate cell elongation, whereas values close to 0 indicate a rounded cell shape. Following 24 h of treatment with 10 mol/L resveratrol ( Fig. 1B) , HUVECs were markedly elongated (EI 0.56 0.02) in contrast to control cells, which were characterized by a rounded cell shape (EI 0.25 0.01). Regarding the timecourse of the observed changes, the cell shape differences between control and resveratrol-treated cells become apparent after 6 h of treatment, indicating a long-term effect on the endothelial cytoskeleton (Fig. 1B) .
RhoA/ROCK are Involved in Endothelial Cell Elongation upon Resveratrol Treatment
To investigate if resveratrol-induced endothelial cell elongation is related to its NF-B inhibitory activity, HUVECs were treated with a specific inhibitor of NF-B pathway BAY11-7082 (1 mol/L). BAY11-7082 was selected for its effectiveness, as it was previously shown to completely abolish TNF--induced expression of endothelial adhesion molecules (10); however, treatment of HUVECs with BAY11-7082 did not evoke any shape changes (not shown), indicating that endothelial cell elongation by resveratrol was not mediated by NF-B inhibition. In contrast, when HUVECs were incubated with 10 mol/L resveratrol in the presence of 1 mol/L simvastatin or ROCK inhibitors (Y27632 at 10 mol/L, or hydroxyfasudil at 20 mol/L), resveratrol-induced elongation was prevented (Fig. 1C) , indicating a role of active RhoA in this process. Increased intracellular cAMP was previously shown to inhibit RhoA activation by its phosphorylation on a serine residue 15) . In agreement with this, treatment with a combination of two cAMP-inducing agents, forskolin (5 mol/L) and rolipram (10 mol/L), abolished the formation of cell-spanning F-actin fibers and prevented cell elongation in response to resveratrol (Fig. 1C) .
Resveratrol Inhibits Spontaneous Endothelial Cell Migration in a ROCK-Dependent Manner
The effect of resveratrol on endothelial cell migration was assessed in a modified barrier assay. HUVECs were cultured in two separated wells for 24 h, followed by treatment with 1-20 mol/L resveratrol overnight. After removal of the barrier, cells were allowed to migrate for up to 27 h in the presence of appropriate concentrations of resveratrol. As shown in Fig. 2A-B , treatment with resveratrol dose-dependently inhibited endothelial cell migration, with a statistically significant reduction at 5 mol/L (p 0.016), as compared to untreated, or ethanol-treated control cells ( Fig. 2B at 24h) .
The effect of resveratrol on endothelial cell migration was not related to its NF-B inhibitory activity, as treatment with NF-B inhibitor BAY11-7082 did not affect migration (cell-covered area at 24h: 79 8% versus 86 3% in control samples). Also, inhibition of SIRT1, endothelial sirtuin, which is activated by resveratrol and involved in vessel growth control, did not significantly reverse the effect of resveratrol: The cellcovered area at 24 h in samples treated with resveratrol in the presence of SIRT1-Inhibitor (1 mol/L) was 43 4%, as compared with 40 4% in samples treated with resveratrol only. Blocking ROCK activity was shown to activate angiogenesis in vitro and in vivo 16) ; therefore, we investigated if inhibition of ROCK signaling induces spontaneous endothelial cell migration and whether it can interfere with the anti-migratory effect of resveratrol. In control cells, inhibition of ROCK with hydroxyfasudil (20 mol/L; Fig. 3A ) significantly induced spontaneous migration. A similar, albeit slightly weaker effect was observed in cells treated with Y27632 (cell-covered area at 24 h: 94 5% versus 86 3% in control samples, Fig. 3A) . To test whether Rho/ROCK signaling is involved in the resveratrol effect on endothelial cell migration, HUVECs were treated with 10 mol/L resveratrol in the presence of ROCK inhibitors, specific cell-permeable Rho inhibitor (C3 transferase, 0.25 g/mL), or simvastatin (1 mol/L). Under these conditions, the anti-migratory effect of resveratrol was strongly reversed by inhibition of ROCK either by hydroxyfasudil or by Y27632 (Fig. 3A) . Comparable results were obtained with the Rho inhibitor C3 transferase (cellcovered area at 24h: 73 8% versus 40 4% in resveratrol-treated samples, Fig. 3B ). In contrast, treatment with simvastatin was less effective (Fig. 3B) . This was likely related to the fact that statins inhibit isoprenylation of other GTPases critically involved in cell , thus blocking cell motility by preventing lamellipodia and filopodia formation. To confirm whether resveratrol exerts an activating effect on endothelial ROCK signaling, we determined the phosphorylation of MYPT1, a downstream target of ROCK. As shown in Fig. 3C , treatment with resveratrol significantly induced MYPT1 phosphorylation in endothelial cells. This induction was abolished in the presence of a ROCK inhibitor, hydroxyfasudil.
Resveratrol Inhibits Monocytic Cell Chemotaxis to MCP-1
Relatively high concentrations of resveratrol (10-100 mol/L) were previously shown to prevent MCP-1 binding to CCR2 in THP-1 monocytic cells 18) ; however, no functional studies have been performed. We therefore investigated whether resveratrol inhibits monocytic chemotaxis to MCP-1. As shown in Fig. 4A-B , resveratrol (1-10 mol/L) reduced monocytic cell chemotaxis towards MCP-1 in a dosedependent manner. There was a statistically significant reduction in the number of migrated adherent cells already at 1 mol/L of resveratrol (n 4, p 0.02 vs control samples). At 10 mol/L resveratrol, the chemotactic response to MCP-1 was reduced nearly to levels comparable with the negative control without chemoattractant ( 90% reduction; n 4, p 0.002 vs positive control, Fig. 4A ). The same pattern was observed when the numbers of transmigrated nonadherent cells in the lower wells were analyzed.
To prove that the observed inhibition of mono- cytic cell migration is resveratrol-specific, an appropriate concentration of ethanol was used as a control. As shown in Fig. 4 , treatment with ethanol did not affect monocytic cell chemotaxis to MCP-1. Furthermore, resveratrol-mediated inhibition of monocytic cell chemotaxis was independent of NF-B, as treatment with NF-B inhibitor BAY11-7082 did not affect chemotaxis. Neither ROCK inhibitors nor cAMP-inducing agents prevented the resveratrol effect on monocytic cell chemotaxis, indicating that its suppressive effect is not mediated by RhoA/ROCK activation (Fig. 4C) .
Binding of MCP-1 to CCR2 on monocytes leads to rapid activation of Ras and to Erk phosphorylation 19) ; therefore, we investigated the effect of resveratrol treatment on Erk phosphorylation upon MCP-1 stimulation. For this purpose, monocytic cells were pretreated with different concentrations of resveratrol overnight followed by stimulation with 50 ng/mL MCP-1 for 10 min. As shown in Fig. 5A , resveratrol dose-dependently inhibited Erk phosphorylation upon MCP-1 activation. At 50 mol/L resveratrol, Erk phosphorylation was reduced to levels comparable (Fig. 5B) . In cells treated with U0126 in the presence of resveratrol, a synergistic effect of both substances was observed, and the number of transmigrated THP-1 cells was reduced nearly to zero. 
Discussion
Resveratrol, the potent anti-inflammatory compound of red wine, has been recently shown to delay atherosclerotic lesion formation in ApoE-deficient mice 20) . With regard to endothelial function, the majority of the atheroprotective activity of resveratrol was thus far believed to originate from the inhibition of pro-inflammatory signaling via suppression of NF-B activity 7, 21, 22) . In accordance with this, we previously demonstrated that resveratrol significantly inhibited adhesion molecule induction and monocytic cell adhesion to TNF--stimulated endothelial cells under hemodynamic conditions corresponding to these in atherosclerosis-prone arterial bifurcations 10) . The current data show that this compound affects endothelial cell morphology and strongly suppresses spontaneous endothelial cell migration. Migration of endothelial cells leads to vessel proliferation and their extension into the intimal regions of atherosclerotic plaque; therefore, inhibition of endothelial migration within growing lesions should contribute to the more effective prevention of plaque progression and its clinical consequences. Pharmacological inhibition of angiogenesis in atherosclerotic plaques, with ensuing inhibition of lesion progression, has been achieved in animal models 23, 24) . In spite of these promising in vivo studies, clinical attempts to inhibit neovascularization in the atherosclerotic arterial wall have been few thus far 25) . Resveratrol was implicated in the inhibition of tumor neovascularization by recent studies 12) , but the mechanisms of its anti-angiogenic effect are far from understood. Resveratrol was shown to activate SIRT1, the main endothelial sirtuin 26) , which is known to control vessel growth under ischemic conditions 27) ; however, as SIRT1-dependent deacetylation either inhibits anti-angiogenic effects of FoxO1 28) , or activates pathways inducing cell migration, such as cortactin 29) , SIRT1 is unlikely to be involved in the resveratrolinduced inhibition of migration. In a very recent study it was shown that resveratrol effect on injuryinduced choroidal neovascularization was independent of SIRT1, and mediated at least in part via AMPK activation 30) . In accordance with these data, our results showed that SIRT1 inhibition did not abolish the inhibitory effect of resveratrol on endothelial cell migration.
One of the proposed cellular mechanisms of antiangiogenic activity of resveratrol is related to the reported binding and inhibition of integrin V 3 by resveratrol 31) , which results in the inhibition of sprouting and tube formation 32) . In the present study, we demonstrated that an additional mechanism involving the ROCK pathway can contribute to the inhibitory activity of resveratrol on endothelial cell migration. As the inhibition of ROCK induces angiogenesis in vitro and in vivo 16) , its activation by resveratrol would be expected to suppress endothelial migration; however, a recently published study on endothelium-denuded aortic rings suggested that resveratrol inhibits ROCK activity and reduces the phosphorylation of MYPT1 in smooth muscle cells 33) . As data regarding resveratrol effects on ROCK pathway activation in endothelial cells have been missing, we investigated endothelial pMYPT1 levels, showing the induction of pMYPT1 in unstimulated endothelial cells upon treatment with resveratrol. These data clearly indicate that resveratrol exhibits cell-specific activity, inducing divergent pathways in different vascular cell types. With regard to endothelial cell migration, it must be noted that resveratrol-induced MYPT1 phosphorylation was nearly completely abolished in the presence of hydroxyfasudil. In contrast, the inhibition of endothelial migration by resveratrol was only partly prevented by ROCK inhibitors, indicating the existence of other, ROCK-independent pathway(s), targeted by resveratrol in endothelial cells. Thus, activation of ROCK signaling by resveratrol may represent an additional pathway modulating spontaneous endothelial cell migration. In contrast to specific ROCK inhibitors, little effect on the inhibition of endothelial migration by resveratrol was observed when the cells were treated with simvastatin. This was not unexpected, as the inhibition of protein isoprenylation by statins affects, apart from RhoA, several other Rho GTPases essential for cell migration 17) , e.g. Rac, which affects lamellipodia formation, or Cdc42 responsible for filopodia extension. Although further studies are required to investigate the inter-relationship of specific endothelial pathways involved in the anti-angiogenic effects of resveratrol, the activation of ROCK signaling may represent one of the mechanisms contributing to the anti-migratory activity of this compound.
Apart from the inhibition of plaque neovascularization, significant protection from atherosclerosis can be achieved by inhibiting monocyte chemotaxis, as evidenced by studies in mice deficient in either MCP-1 34) or its receptor CCR2 35) . Resveratrol has been previously reported to inhibit interleukin 1 -induced endothelial production of MCP-1 36) , and to prevent MCP-1 binding to CCR2 in THP-1 monocytic cells 18) . We have demonstrated that these effects translate into functional suppression of monocytic cell migration towards MCP-1, with statistically significant inhibition already at 1 mol/L resveratrol. This effect was independent of NF-B inhibitory activity of resveratrol, and was not prevented by inhibition of the RhoA/ROCK pathway. In MCP-1 signaling downstream of CCR2, rapid Erk activation followed by the activation of integrins and chemotaxis was described 19) . The inhibition of Erk is thus expected to prevent monocytic cell migration. As shown in our study, resveratrol treatment was associated with the dose-dependent inhibition of Erk phosphorylation upon MCP-1 stimulation; however, resveratrol suppressed monocytic cell chemotaxis to a greater degree than a specific inhibitor of Erk phosphorylation U0126, indicating that inhibition of Erk phosphorylation represents only one of the pathways involved in the anti-chemotactic effect of resveratrol. In light of existing in vivo data on the role of MCP-1 in atherosclerosis, inhibition of MCP-1-stimulated monocytic cell migration by resveratrol, and the extent of this effect, may represent one of the most important mechanisms of its cardioprotective activity.
With regard to resveratrol bioavailability, it must be noted that although the anti-inflammatory activity of resveratrol was observed already at 100 nmol/L concentrations in vitro 7) , much higher doses (10-100 mol/L) were needed to inhibit cancer cell migration 11) , or to activate SIRT1 9) . After the intake of 300 mL red wine rich in stilbenes, peak stilbene concentration in plasma was reported to reach 10 mol/L, or about 4 mol/L resveratrol 6) , although glucuronidation in the liver may reduce the bioavailability of the free compound to nanomolar concentrations. As dietary flavonoids were shown to inhibit the glucuronidation of resveratrol in human liver 37) thus improving its bioavailability, resveratrol concentrations used in the present study, although somewhat higher than achievable with red wine intake, are within the levels achievable with diet supplements containing higher doses (gram levels) of this compound. Moreover, its apparent pharmacologic safety 38, 20) , along with increased understanding of its pleiotropic activities, may help optimize the use of resveratrol in the treatment and prevention of cardiovascular disease.
In conclusion, the considerable preventive and therapeutic potential of resveratrol in atherosclerotic disease merits wider recognition. Suppression of endothelial and monocytic migration, as well as the previously reported inhibition of leukocyte-endothelial interactions, represent important mechanisms in resveratrol-mediated atheroprotection. Clinical studies will be necessary to determine whether these in vitro effects of resveratrol can translate into a long-term cardiovascular benefit associated with persisting plaque regression.
